MA43767B1 - Anticorps non antagonistes dirigés contre la chaine alpha du domaine extracellulaire du récepteur de l'il-7 et leur utilisation dans le traitement du cancer - Google Patents

Anticorps non antagonistes dirigés contre la chaine alpha du domaine extracellulaire du récepteur de l'il-7 et leur utilisation dans le traitement du cancer

Info

Publication number
MA43767B1
MA43767B1 MA43767A MA43767A MA43767B1 MA 43767 B1 MA43767 B1 MA 43767B1 MA 43767 A MA43767 A MA 43767A MA 43767 A MA43767 A MA 43767A MA 43767 B1 MA43767 B1 MA 43767B1
Authority
MA
Morocco
Prior art keywords
receptor
extracellular domain
alpha chain
directed against
antibodies directed
Prior art date
Application number
MA43767A
Other languages
English (en)
Other versions
MA43767A (fr
Inventor
Nicolas Poirier
Caroline Mary
Original Assignee
Ose Immunotherapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ose Immunotherapeutics filed Critical Ose Immunotherapeutics
Publication of MA43767A publication Critical patent/MA43767A/fr
Publication of MA43767B1 publication Critical patent/MA43767B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624—Disulfide-stabilized antibody (dsFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des anticorps humanisés dirigés contre le domaine extracellulaire de la chaîne alpha du récepteur de l'interleukine-7 (il-7), notamment contre le récepteur de l'il-7 humaine exprimé sur les cellules humaines (également appelé il-7ralpha ou il-7ra ou cd127 humain) et qui n'interfèrent pas avec les voies de signalisation de l'il-7 ou du tslp. Les anticorps de la présente invention ne présentent pas un effet antagoniste sur le récepteur de l'il-7, mais peuvent toujours présenter une activité cytotoxique contre des cellules cd127 positives. Dans un mode de réalisation particulier, l'anticorps ne présente pas un effet agoniste sur le récepteur de l'il-7.
MA43767A 2016-02-29 2017-02-28 Anticorps non antagonistes dirigés contre la chaine alpha du domaine extracellulaire du récepteur de l'il-7 et leur utilisation dans le traitement du cancer MA43767B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662301271P 2016-02-29 2016-02-29
PCT/IB2017/000293 WO2017149394A1 (fr) 2016-02-29 2017-02-28 Anticorps non antagonistes dirigés contre la chaine alpha du domaine extracellulaire du récepteur de l'il-7 et son utilisation dans le traitement du cancer

Publications (2)

Publication Number Publication Date
MA43767A MA43767A (fr) 2019-01-09
MA43767B1 true MA43767B1 (fr) 2019-08-30

Family

ID=58530580

Family Applications (1)

Application Number Title Priority Date Filing Date
MA43767A MA43767B1 (fr) 2016-02-29 2017-02-28 Anticorps non antagonistes dirigés contre la chaine alpha du domaine extracellulaire du récepteur de l'il-7 et leur utilisation dans le traitement du cancer

Country Status (23)

Country Link
US (1) US11230602B2 (fr)
EP (1) EP3423496B1 (fr)
JP (1) JP7053479B2 (fr)
KR (1) KR20180118746A (fr)
CN (1) CN109195987B (fr)
AU (1) AU2017225495B2 (fr)
BR (1) BR112018067479A2 (fr)
CA (1) CA3014313A1 (fr)
CY (1) CY1122072T1 (fr)
DK (1) DK3423496T3 (fr)
ES (1) ES2737307T3 (fr)
HR (1) HRP20191445T1 (fr)
HU (1) HUE045183T2 (fr)
IL (1) IL261330B2 (fr)
LT (1) LT3423496T (fr)
MA (1) MA43767B1 (fr)
MD (1) MD3423496T2 (fr)
ME (1) ME03446B (fr)
PL (1) PL3423496T3 (fr)
PT (1) PT3423496T (fr)
RS (1) RS59223B1 (fr)
SI (1) SI3423496T1 (fr)
WO (1) WO2017149394A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2955196A1 (fr) 2014-06-10 2015-12-16 Effimune Anticorps dirigés contre CD127
US20200362300A1 (en) * 2017-08-29 2020-11-19 Ose Immunotherapeutics Method and preparation for sorting out t effector cells using anti-cd127 antibodies for applications in cell therapy
US11970532B2 (en) * 2018-05-10 2024-04-30 Neuracle Science Co., Ltd. Anti-family with sequence similarity 19, member A5 antibodies and method of use thereof
KR20220100567A (ko) * 2019-06-28 2022-07-15 더 유니버시티 오브 멜버른 감마 델타 t 세포의 억제 또는 활성화 방법
CN110894237B (zh) * 2019-12-05 2021-08-03 山东省分析测试中心 抗cd127的抗体、分泌该抗体的细胞株及其制备方法和应用
CA3181394A1 (fr) * 2020-04-27 2021-11-04 Memorial Sloan-Kettering Cancer Center Recepteur antigenique chimerique ciblant cd127 et utilisation associee
CA3179308A1 (fr) * 2020-05-18 2021-11-25 Hassan JUMAA-WEINACHT Composition pour le traitement de la leucemie lymphoblastique aigue positive au chromosome philadelphie
CN113501878B (zh) * 2021-02-03 2022-12-02 北京智仁美博生物科技有限公司 针对人tslp的多种抗体及其用途
US20220389104A1 (en) * 2021-05-28 2022-12-08 Ose Immunotherapeutics Method for Treating CD127-Positive Cancers by Administering an Anti-CD127 Agent

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
EP3431585A1 (fr) 2006-05-31 2019-01-23 The Regents of The University of California Expression cd127 inversement corrélée avec foxp3 et fonction suppressive de tregs cd4+
ATE542830T1 (de) 2006-12-04 2012-02-15 Pasteur Institut Als gerüst verwendeter ob-fold zur entwicklung neuer spezifischer bindemittel
GB0724051D0 (en) 2007-12-08 2008-01-16 Medical Res Council Mutant proteins and methods for producing them
TW201018482A (en) 2008-08-08 2010-05-16 Glaxo Wellcome Mfg Pte Ltd Novel treatment
WO2010085643A1 (fr) 2009-01-22 2010-07-29 University Of Miami Ciblage de la signalisation il-7 à des fins de traitement de la sclérose en plaques et d'autres troubles dépendant de la signalisation il-7
AU2011209713B2 (en) * 2010-01-28 2014-04-03 Glaxo Group Limited CD127 binding proteins
AR080291A1 (es) * 2010-02-24 2012-03-28 Rinat Neuroscience Corp Anticuerpos antagonistas anti receptor de il-7 y procedimientos
EP2583980A1 (fr) 2011-10-19 2013-04-24 Effimune Anticorps dirigés contre la chaîne alpha du récepteur IL7, leur utilisation pour la préparation de candidats médicaments
US20150297310A1 (en) 2014-04-17 2015-10-22 Georgia Regents Research Institute, Inc. Methods for selecting a treatment for cancer
EP2955196A1 (fr) 2014-06-10 2015-12-16 Effimune Anticorps dirigés contre CD127

Also Published As

Publication number Publication date
IL261330A (en) 2018-10-31
AU2017225495B2 (en) 2024-05-09
ME03446B (fr) 2020-01-20
US20200308288A1 (en) 2020-10-01
EP3423496A1 (fr) 2019-01-09
JP2019515648A (ja) 2019-06-13
AU2017225495A1 (en) 2018-08-23
MD3423496T2 (ro) 2020-01-31
KR20180118746A (ko) 2018-10-31
PT3423496T (pt) 2019-09-05
CN109195987A (zh) 2019-01-11
RS59223B1 (sr) 2019-10-31
DK3423496T3 (da) 2019-08-19
LT3423496T (lt) 2019-09-25
CA3014313A1 (fr) 2017-09-08
MA43767A (fr) 2019-01-09
HRP20191445T1 (hr) 2019-11-15
IL261330B2 (en) 2023-03-01
HUE045183T2 (hu) 2019-12-30
JP7053479B2 (ja) 2022-04-12
US11230602B2 (en) 2022-01-25
EP3423496B1 (fr) 2019-07-03
CN109195987B (zh) 2022-05-27
WO2017149394A1 (fr) 2017-09-08
PL3423496T3 (pl) 2020-01-31
CY1122072T1 (el) 2020-11-25
IL261330B (en) 2022-11-01
BR112018067479A2 (pt) 2019-01-15
ES2737307T3 (es) 2020-01-13
SI3423496T1 (sl) 2019-10-30

Similar Documents

Publication Publication Date Title
MA43767B1 (fr) Anticorps non antagonistes dirigés contre la chaine alpha du domaine extracellulaire du récepteur de l'il-7 et leur utilisation dans le traitement du cancer
CO2019012353A2 (es) Formulaciones de anticuerpos anti-lag3 y coformulaciones de anticuerpos anti-lag3 y anticuerpos anti-pd-1
MA39313A1 (fr) Anticorps anti-egfrviii et leurs utilisations dans le traitement de divers cancers
MA40497A (fr) Anticorps et récepteurs antigéniques chimériques spécifiques du cd19
EA202190377A1 (ru) Композиции ингибиторов cxcr4 и способы получения и применения
HN2012001223A (es) Antagonistas de pcsk 9
CL2016003172A1 (es) Anticuerpos dirigidos contra cd127
CR8891A (es) Antagonismo de la actividad del receptor de interleuquina 21
CO2021011198A2 (es) Receptores de citocinas quiméricos constitutivamente activos
MX2022006962A (es) Receptor quimerico de antigenos basado en el miembro 1 de la subfamilia b de receptores similares a inmunoglobulina de leucocitos (lilrb1).
PH12020551144A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
MA49727B1 (fr) Anticorps et polypeptides dirigés contre cd127
MX2020008106A (es) Moduladores del receptor nmda espiro-lactama y usos de los mismos.
MA37945A1 (fr) Anticorps humains dirigés contre le gfr?3 et méthodes d'utilisation associées
EA202090204A1 (ru) Анти-cd137 антитела
CR9428A (es) Metodos para el tratamiento y la prevencion de fibrosis
MX2009008918A (es) Activacion de celulas que presentan antigeno humano a traves de clec-6.
CR20200404A (es) Anticuerpos anti-klk5 y métodos de uso
MX2021012692A (es) Anticuerpos anti-mertk y sus metodos de uso.
CR20200313A (es) VARIANTES DE DOMINIO DE Fc DE IgG HUMANA CON FUNCIÓN EFECTIVA MEJORADA
MX2022001146A (es) Formulaciones de anticuerpos anti-pvrig y sus usos.
PH12021550289A1 (en) Ox40-binding polypeptides and uses thereof
EA202092508A1 (ru) Составы на основе антител к pd-l1 человека
PH12020551985A1 (en) Anti-human tlr7 antibody
EP4257195A3 (fr) Anticorps anti-cfae et méthodes d'utilisation